# Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures

> **NCT00384358** · PHASE2 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 108 (actual)

## Conditions studied

- Fractures

## Interventions

- **DRUG:** rhBMP-2/CPM
- **DRUG:** rhBMP-2/CPM
- **OTHER:** surgical intervention alone

## Key facts

- **NCT ID:** NCT00384358
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2013-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00384358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00384358, "Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00384358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*